Intercept Pharmaceuticals' Above $300 -- More Mega Millions On The Way?

Jan 17 2014, 1:53pm CST | by

Anyone following the stock of Intercept Pharmaceuticals (NASDAQ:ICPT) closely cannot help but get dizzy. After racing from $72 to $497 last week, the stock corrected sharply this week–trading below $250 early in the week, before recovering nicely to above $300 in the last two days.

Does this mean that the correction is over? Are more mega millions on the way for the company’s shareholders?

We cannot say. What we can say is that this is a highly speculative stock for investors who have faith in the company’s prospects.

Intercept Pharmaceuticals develops innovative treatment for chronic diseases likeobeticholic acid, a bile acid analog (OCA), which is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea.

That certainly sounds like a very promising compound, and last week it performed unexpectedly well in a clinical trial, sending the company’s stock soaring — as this development makes it very likely that the compound will receive FDA approval.

As one of commentators observed in a previous piece:

“People bid up stock for market potential. Stock trading is speculative in nature and nothing is pure black and white in the Bio-tech world. I think you need to understand some fundamentals of the statistics and clinical trials before you can comment on the likelihood of FDA approval. Currently, what investors perceived is based on 5% type I error rate. The actual error rate is much much smaller than 5%, given the fact that the phase II clinical trial was stopped much earlier than designed.”

Even so, before rushing to buy the stock at these levels, investors should understand three things:

First, we are still talking about a drug that is very likely to win FDA approval, not a drug that has already received approval.

Second, even if OCA passes the FDA test, it must subsequently pass the market test. Investors have to look no further than the fate of Dendreon’s drug PROVENGE and Affymax’s drug OMONTYS, neither of which performed well in market tests.

Third, even if OCA passes both the FDA and the market test, at the current market valuation, the company is valued close to 7 percent of the value of Amgen Inc., which has been around for more than three decades and has several blockbuster stocks in the market.

A valuation such as this makes Intercept Pharmaceuticals hardly a bargain, even if it successfully passes the FDA and the market test. That’s why I’ll still stay away from the stock.

Source: Forbes Business

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Oops! US Airways Didn't Mean To Post THAT Tweet
Oops! US Airways Didn't Mean To Post THAT Tweet
US Airways has been left red-faced after posting an embarrassing tweet on its official Twitter account. The error is the latest in a line of gaffes by different companies on social media, highlighting the problems many...
 
 
A Lucky Drug Made Pharmacyclics' Robert Duggan A Billionaire. Will Long-Term Success Follow?
A Lucky Drug Made Pharmacyclics' Robert Duggan A Billionaire. Will Long-Term Success Follow?
Robert Duggan was enjoying just your average Tampa vacation–a visit to the headquarters of the Church of Scientology, to which he’s a major donor, and a double date with one of the world’s top supermodels–when a board...
 
 
Emerging Markets: Separating The Sheep And The Goats
Investors who thought emerging markets were the bee’s knees have suffered agonizing reappraisals. After several years of Federal Reserve-fueled rallies, less developed markets are now in the doldrums. Emerging economies...
 
 
Tencent WeChat and SINA Weibo: The Frenemies of the Chinese Mobile Space
Tencent WeChat and SINA Weibo: The Frenemies of the Chinese Mobile Space
Once the darling of tech investors, Sina (NASDAQ: SINA) Weibo failed to excite Asian investors during its pre-IPO investor education in Hong Kong last week. Sina is expected to spin off its Weibo social networking...
 
 
 

Latest from the Network

Oops! US Airways Didn't Mean To Post THAT Tweet
US Airways has been left red-faced after posting an embarrassing tweet on its official Twitter account. The error is the latest in a line of gaffes by different companies on social media, highlighting the problems many...
Read more on Business Balla
 
A Lucky Drug Made Pharmacyclics' Robert Duggan A Billionaire. Will Long-Term Success Follow?
Robert Duggan was enjoying just your average Tampa vacation–a visit to the headquarters of the Church of Scientology, to which he’s a major donor, and a double date with one of the world’s top supermodels–when a board...
Read more on Business Balla
 
Emerging Markets: Separating The Sheep And The Goats
Investors who thought emerging markets were the bee’s knees have suffered agonizing reappraisals. After several years of Federal Reserve-fueled rallies, less developed markets are now in the doldrums. Emerging economies...
Read more on Business Balla
 
Tencent WeChat and SINA Weibo: The Frenemies of the Chinese Mobile Space
Once the darling of tech investors, Sina (NASDAQ: SINA) Weibo failed to excite Asian investors during its pre-IPO investor education in Hong Kong last week. Sina is expected to spin off its Weibo social networking...
Read more on Business Balla
 
Voices From The Vineyard: Fado Singing In The Duoro Valley
This series, Voices from the Vineyard, shines a light on the people who actually do the work — the physical labor — of making wine in the field. Though it is often overlooked in favor of the winemaking part of the...
Read more on Business Balla
 
The Next Big Business Buzzword: Ecosystem?
Words are funny things.  Business words are even funnier. That’s because, in actuality, there aren’t that many new business ideas.  Most of the time, we just slap new labels onto old things.  For example, your “core...
Read more on Business Balla
 
Has Healthcare Embraced A Hit-And-Run Strategy?
Sovaldi is off to the races — the biggest and most successful drug launch, by far, in the history of the industry. This is a truly remarkable achievement, a combination of derring-do and flawless execution that has...
Read more on Business Balla
 
Energy Companies Need To Remake Their Boards, Before Activists Force Them To
This is a guest article written by Steven Goodman, Roger Aguirre and Avery Marcus in the Global Energy Practice of Egon Zehnder. The firm specializes in CEO and senior-level executive search, board consulting and...
Read more on Business Balla
 
Court rejects bankruptcy protection for Mt. Gox
TOKYO (AP) — The Mt. Gox bitcoin exchange in Tokyo is headed for liquidation after a court rejected its bankruptcy protection application. Mt. Gox said Wednesday the Tokyo District Court decided the...
Read more on Business Balla
 
 
Auto Balla Sexy Balla Sport Balla TV Balla Politics Balla Movie Balla Apple Balla Business Balla Ad Balla Celebrity Balla